TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AdAlta Ltd. ( (AU:1AD) ) has provided an update.
AdAlta Limited has made significant progress in its ‘East to West’ cellular immunotherapy strategy, with advanced licensing negotiations for its first CAR-T product and plans for a multi-asset collaboration on a second product. The company has strengthened its financial position by raising $1.6 million through market placements and repaying investments, which enhances its negotiating power and potential ownership in its AdCella subsidiary. These developments position AdAlta to leverage its expertise in cellular immunotherapy and expand its market reach, potentially increasing its value and impact in the biotechnology sector.
More about AdAlta Ltd.
AdAlta Limited is a biotechnology company specializing in the development of next-generation protein and cell therapeutic products. The company focuses on cellular immunotherapies, particularly CAR-T products, and aims to bridge Asian innovations with Western-regulated markets through its ‘East to West’ strategy.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$8.45M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.